Updates on the multimodality management of desmoplastic small round cell tumor.
Desmoplastic Small Round Cell Tumor (DSRCT) is a rare and an aggressive malignancy with poor outcome. This tumor can co-express epithelial, neural, and mesenchymal markers. The molecular hallmark of DSRCT is the EWS-WT1 fusion protein. Despite the diversities in treatment modality, the best results have been seen with radical surgery and adjuvant or neoadjuvant chemotherapy.
Department of Surgical Oncology, All India Institute of Medical Science, New Delhi, India. docash04@yahoo.com
Ashwin A
AA
Kallianpur
Nootan K
NK
Shukla
Suryanarayan V S
SV
Deo
Praveen
P
Yadav
Dillip
D
Mudaly
Rajni
R
Yadav
Ramanathan M
RM
Palaniappan
D000008:Abdominal Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D058405:Desmoplastic Small Round Cell Tumor / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced; D007150:Immunohistochemistry; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D018714:Radiotherapy, Adjuvant; D014057:Tomography, X-Ray Computed; D014178:Translocation, Genetic
D000911:Antibodies, Monoclonal; C106032:EWS1-WT1 fusion protein, human; D015514:Oncogene Proteins, Fusion